Evoke Pharma, Inc. (EVOK)

NASDAQ: EVOK · IEX Real-Time Price · USD
2.12
-0.16 (-7.02%)
At close: Mar 28, 2023, 4:00 PM
2.22
+0.10 (4.72%)
After-hours: Mar 28, 2023, 5:38 PM EDT
-7.02%
Market Cap 7.09M
Revenue (ttm) 2.51M
Net Income (ttm) -8.22M
Shares Out 3.34M
EPS (ttm) -2.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 29,822
Open 2.27
Previous Close 2.28
Day's Range 2.00 - 2.32
52-Week Range 1.37 - 16.80
Beta 0.40
Analysts Buy
Price Target 7.14 (+236.79%)
Earnings Date May 9, 2023

About EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incor... [Read more]

Sector Healthcare
IPO Date Sep 25, 2013
Employees 4
Stock Exchange NASDAQ
Ticker Symbol EVOK
Full Company Profile

Financial Performance

In 2022, Evoke Pharma's revenue was $2.51 million, an increase of 55.04% compared to the previous year's $1.62 million. Losses were -$8.22 million, -3.68% less than in 2021.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for EVOK stock is "Buy." The 12-month stock price forecast is $7.14, which is an increase of 236.79% from the latest price.

Price Target
$7.14
(236.79% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023

Data Demonstrated Reduced Use of Healthcare Resources among Patients Treated with GIMOTI Data Demonstrated Reduced Use of Healthcare Resources among Patients Treated with GIMOTI

5 days ago - GlobeNewsWire

Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results

Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021 Patient enrollment increased by 149% compared with 2021

1 week ago - GlobeNewsWire

Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023

SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with a...

1 week ago - GlobeNewsWire

Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session

Distinguished event features the year's best abstracts and invited speakers in their fields Distinguished event features the year's best abstracts and invited speakers in their fields

1 month ago - GlobeNewsWire

Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

Stipulation of Dismissal of Claims, Defenses and Counterclaims for Patent Infringement Case Filed Stipulation of Dismissal of Claims, Defenses and Counterclaims for Patent Infringement Case Filed

2 months ago - GlobeNewsWire

Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

Real-world study compares diabetic gastroparesis patient utilization of healthcare resources before and after initiation of GIMOTI Real-world study compares diabetic gastroparesis patient utilization ...

2 months ago - GlobeNewsWire

USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis

SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...

3 months ago - GlobeNewsWire

Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®

SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...

4 months ago - GlobeNewsWire

Evoke Pharma to Report Third Quarter Results on November 9, 2022

SOLANA BEACH, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced ...

5 months ago - GlobeNewsWire

Evoke Pharma to Participate in the 2022 American College of Gastroenterology Annual Scientific Meeting

Company will exhibit Gimoti® and meet with Key Opinion Leaders

5 months ago - GlobeNewsWire

Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI

SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with a...

6 months ago - GlobeNewsWire

GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award

GIMOTI recognized as a major disruptor in the gastroenterology field, including several large global pharmaceutical companies

6 months ago - GlobeNewsWire

Evoke Pharma to Participate in H.C. Wainwright 24th Annual Global Investment Conference

SOLANA BEACH, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today...

7 months ago - GlobeNewsWire

Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth Solution

Patients With Symptoms of Diabetic Gastroparesis Now Have Direct-to-Patient Treatment Support Powered by UpScriptHealth Patients With Symptoms of Diabetic Gastroparesis Now Have Direct-to-Patient Trea...

8 months ago - GlobeNewsWire

Evoke Pharma Reports Second Quarter 2022 Financial Results

Total new inbound prescriptions over 500 for first time, 24% increase over Q1; New cumulative prescribers up 23%; Net revenue increased by 11% Total new inbound prescriptions over 500 for first time, ...

8 months ago - GlobeNewsWire

Evoke Pharma to Report Second Quarter Results on August 10, 2022

SOLANA BEACH, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced ...

8 months ago - GlobeNewsWire

Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)

Ranked #1 in IFFGD Virtual Walk to spread awareness and support research for gastrointestinal disorders

8 months ago - GlobeNewsWire

Evoke Pharma (EVOK) Stock Soars 50% on Medicaid Drug Approval

Evoke Pharma (EVOK) stock is rocketing higher on Wednesday after the company got Medicaid approval for its GIMOTI nasal spray. The post Evoke Pharma (EVOK) Stock Soars 50% on Medicaid Drug Approval ap...

10 months ago - InvestorPlace

Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

SOLANA BEACH, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...

10 months ago - GlobeNewsWire

Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

SOLANA BEACH, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...

10 months ago - GlobeNewsWire

Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported

Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients treated with metoclopramide

11 months ago - GlobeNewsWire

Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022

SOLANA BEACH, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced t...

11 months ago - GlobeNewsWire

Why Is Evoke Pharma (EVOK) Stock Up 130% Today?

Evoke Pharma is up an unbelievable 130% today on news of recently granted drug exclusivity. How high will EVOK stock soar?

1 year ago - InvestorPlace

Evoke Shares Skyrocket On New FDA Market Exclusivity For Gimoti Nasal Spray

The FDA has granted new drug product exclusivity to Evoke Pharma Inc's (NASDAQ: EVOK) Gimoti (metoclopramide) nasal spray to relieve symptoms associated with acute and recurrent diabetic gastroparesis...

1 year ago - Benzinga

Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results

Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3  Easing of COVID-19 restrictions helped fuel higher sales, increased face-to-face meetings with healthcare pr...

1 year ago - GlobeNewsWire